Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid c... скачать в хорошем качестве

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid c...

Prof Vivek Subbiah speaks to ecancer about the ongoing LIBRETTO-001 study he presented at this year's virtual AACR 2021 meeting looking at the efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers. He explains that selpercatinib has proven effective in non-small cell lung cancer and thyroid cancer and has been approved for use in multiple countries. Prof Subbiah reports that selpercatinib is showing promising ant-tumour activity in this cohort which includes multiple treatment-refractory GI malignancies. He also covers the safety aspect highlighting that no patients discontinued treatment due to a treatment related adverse event. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php